Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today that it has received approval from the TSX Venture Exchange to extend the expiry of 1,140,000 outstanding common share purchase warrants (the “Warrants”) of the Company, which were issued in connection with the Company’s August 2010 private placement financing.
Help employers find you! Check out all the jobs and post your resume.
TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today that it has received approval from the TSX Venture Exchange to extend the expiry of 1,140,000 outstanding common share purchase warrants (the “Warrants”) of the Company, which were issued in connection with the Company’s August 2010 private placement financing.
Help employers find you! Check out all the jobs and post your resume.